Latest filing published 03 Nov 2025 for BIO-TECHNE Corp. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Rupert Vessey (senior executive) discloses dealings in 2 companies, chiefly Bristol Myers Squibb Co and BIO-TECHNE Corp. In total, 20 filings cover trades dated from 5 May 2021 to 30 October 2025.
Sales make up the whole of the open-market record (5 sales, €8.0M). The rest of the record consists of 6 share grants and 9 option exercises.
On 3 November 2025 came the latest disclosure, a share grant in BIO-TECHNE Corp. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
20 of 20 declarations